首页/数据集/Dataset from Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children

Dataset from Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children

NIAID Data Ecosystem2026-05-02 收录

疫苗临床试验

免疫原性与安全性评估

数据链接：

https://doi.org/10.25934/00000837 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of the present study is to assess the immunogenicity and safety of vaccine GSK2321138A in children.

应用场景：

创建时间：

2024-11-27

癌症免疫治疗

疫苗临床试验

BackgroundImmune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identifie

NIAID Data Ecosystem70

Dataset from Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants

疫苗临床试验

结核病预防

This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme

NIAID Data Ecosystem20

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

疫苗临床试验

疫苗免疫原性与安全性评估

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

NCATS Open Data2024-08-16 更新10

Predictors of consenting to mucosal secretion sampling amongst volunteers screened for HVTN 097.

疫苗临床试验

生物样本采集行为预测

*OR = Odds Ratio. **95% CI = 95% confidence interval. †AOR = Adjusted Odds Ratio. Predictors of consenting to mucosal secretion sampling amongst volunteers screened for HVTN 097.

NIAID Data Ecosystem30

Dataset from Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.

疫苗临床试验

免疫原性评估

This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older. This study is also designed to assess the lot

NIAID Data Ecosystem20

Dataset from Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children

资源简介：

相关数据集